Pascal Touchon, Atara Biotherapeutics CEO

Atara Bio­ther­a­peu­tic­s' stock drops near­ly 50% af­ter PhII tri­al fail in MS

Atara Bio­ther­a­peu­tics’ cell ther­a­py flunked a Phase II study in pro­gres­sive mul­ti­ple scle­ro­sis, miss­ing the pri­ma­ry end­point as well as flu­id and imag­ing bio­mark­ers, …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.